Health state utilities for metastatic breast cancer
Top Cited Papers
Open Access
- 12 September 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 95 (6), 683-690
- https://doi.org/10.1038/sj.bjc.6603326
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a surveyJournal of Clinical Epidemiology, 2005
- The meaning of quality of life in patients being treated for advanced breast cancer: A qualitative studyPsycho‐Oncology, 2004
- Goals and Objectives in the Management of Metastatic Breast CancerThe Oncologist, 2003
- The evolving experience of illness for Chinese women with breast cancer: A qualitative studyPsycho‐Oncology, 2002
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast CancerPharmacoEconomics, 1996
- Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast CancerJAMA, 1992
- Measurement of health state utilities for economic appraisal: A reviewJournal of Health Economics, 1986